晚期三阴性乳腺癌一线治疗GP方案和TAC方案疗效对比

摘要

Objective To compare the effect of GP scheme and TAC scheme as first-line treatment in treating triple-negative breast cancer. Methods 68 patients with triple-negative breast cancer were selected, they were randomly divided in-to the observation group and the control group, 34 cases each. The observation group was given GP scheme combined chemotherapy, while the control group was given TAC scheme combined chemotherapy. The clinical efficacy, adverse reaction and clinical benefit response were compared between the two groups after the treatment. Results The total effective rate was 47.06%in the observation group, no significant difference with the control group (50%), P>0.05. The bone marrow suppression of second degree and third degree and above were 20 cases, 14 cases in the observation group, while they were 13 cases, 21 cases in the control group, the bone marrow toxicity was significant difference between the two groups (P<0.05). The gastroin-testinal reaction above Ⅱ degree was 19 cases in observation group, it was 10 cases in the control group. There was significant difference between the two groups (P<0.05). Two groups of patients with fever, allergic reaction, mild abnormal electrocardio-gram, EF (left ventricular ejection fraction) and other toxic and side reaction were not significantly different (P>0.05). The clinical benefit response rate of observation group was 55.88%, while 50%in the control group. There was no significant differ-ence between the two groups (P>0.05). Conclusion GP scheme and TAC scheme combined with chemotherapy have good curative effect in treating triple-breast cancer at first-line therapy.%目的：比较GP和TAC两种化疗方案用于晚期三阴性乳腺癌患者一线治疗的临床效果。方法晚期三阴性乳腺癌患者68例，按随机数字表法分为观察组和对照组，各34例。观察组给予GP两药联合化疗，对照组给予TAC三药联合化疗，比较两组患者治疗后的临床疗效、毒副反应发生情况及临床受益反应。结果观察组患者治疗总有效率为47.06%，与对照组患者的50.00%比较无明显差异（P＞0.05）。观察组骨髓抑制Ⅱ度及Ⅲ度以上分别为20例、14例，对照组为13例、21例，对照组患者骨髓毒性大于观察组，组间存在显著性差异（P＜0.05）。观察组胃肠道反应Ⅱ度以上为19例，对照组为10例。观察组胃肠道反应严重程度明显高于对照组（P＜0.05）。两组患者发热、过敏反应、轻度心电图异常、EF（心脏射血分数）等毒副反应发生情况均无明显差异（P＞0.05）。观察组临床受益反应率为55.88%，对照组为50.00%，组间无明显差异（P＞0.05）。结论 GP两药联合方案和TAC三药联合化疗方案，用于晚期三阴性乳腺癌患者一线治疗，疗效相当。